Valuation: Fulgent Genetics, Inc.

Market Cap 513M 443M 416M 379M 712M 49.09B 722M 4.87B 1.91B 24.59B 1.93B 1.89B 81.81B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 513M 443M 416M 379M 712M 49.09B 722M 4.87B 1.91B 24.59B 1.93B 1.89B 81.81B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.34x
Free-Float
48.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week-2.44%
Current month-2.44%
1 month-8.57%
3 months+19.40%
6 months-19.19%
Current year-28.57%
1 week 16
Extreme 16
16.4
1 month 14.3
Extreme 14.3
17.5
Current year 11.8
Extreme 11.8
24.6
1 year 11.8
Extreme 11.8
26.6
3 years 11.8
Extreme 11.8
31
5 years 11.8
Extreme 11.8
92.94
10 years 5.95
Extreme 5.95
150
Manager TitleAgeSince
President 59 2022-05-02
Chief Executive Officer 70 2016-05-12
Director of Finance/CFO 58 2015-12-31
Director TitleAgeSince
Chairman 70 2016-08-31
Director/Board Member 76 2019-07-31
Director/Board Member 57 2022-07-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-2.44% - - 513M
+1.37%-1.31%+92.72%+504.54% 45.29B
+1.64%+0.63%+19.59%+51.87% 26.22B
+0.92%+1.86%-19.23%-29.32% 8.01B
-0.55%-1.75%+12.57%+158.79% 5.98B
+1.21%-2.52%+10.87%+69.56% 3.28B
-0.88%-0.63%-38.75%+1,405.64% 2.31B
+1.38%-2.83%+160.23%+18.30% 2.08B
-3.36%-6.14%-3.68%-55.98% 2B
-0.49%-3.61%+28.84%+20.13% 1.9B
Average +0.19%-1.34%+29.24%+238.17% 10.78B
Weighted average by Cap. +1.09%-0.39%+51.10%+292.19%

Financials

2026 *2027 *
Net sales 332M 286M 269M 245M 460M 31.71B 466M 3.15B 1.23B 15.89B 1.25B 1.22B 52.85B 383M 330M 310M 282M 531M 36.59B 538M 3.63B 1.42B 18.33B 1.44B 1.41B 60.98B
Net income -112M -96.69M -90.71M -82.62M -155M -10.71B -158M -1.06B -417M -5.37B -420M -411M -17.85B -79M -68.2M -63.98M -58.28M -110M -7.55B -111M -750M -294M -3.78B -297M -290M -12.59B
Net Debt - -
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change
26-08-18 16.00 0.00%
26-08-17 €16.00 0.00%
26-08-14 €16.00 -0.62%
26-08-13 €16.10 -1.83%
26-08-12 €16.40 0.00%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
18.66USD
Average target price
19.00USD
Spread / Average Target
+1.82%

Quarterly revenue - Rate of surprise